Eradication of therapy-resistant human prostate tumors using a cancer terminator virus

Cancer Research

Volumn 67, Issue 11, 2007, Pages 5434-5442

  Sarkar, Devanand ^a   Lebedeva, Irina V ^a   Su, Zao Zhong ^a   Park, Eun Sook ^a   Chatman, Lejuan ^a   Vozhilla, Nicollaq ^a   Dent, Paul ^b   Curiel, David T ^c   Fisher, Paul B ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 24; PROTEIN BCL 2; PROTEIN BCL XL;

ADENOVIRUS; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TERMINATOR VIRUS; CYTOKINE RELEASE; GENE EXPRESSION; GENE REPLICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; TUMOR XENOGRAFT; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, DIFFERENTIATION; BCL-X PROTEIN; CELL LINE, TUMOR; GENE THERAPY; HUMANS; INTERLEUKINS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34347216741     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0195     Document Type: Article

References (50)

1. Sternberg CN. Highlights of contemporary issues in the medical management of prostate cancer. Crit Rev Oncol Hematol 2002;43:105-21.
2. Di Lorenzo G, De Placido S. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int J Immunopathol Pharmacol 2006;19:11-34.
3. Dyrstad SW, Shah P, Rao K. Chemotherapy for prostate cancer. Curr Pharm Des 2006;12:819-37.
4. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormonerefractory human prostate cancers. Am J Pathol 1993;143:390-400.
5. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
6. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994;54:5501-7.
7. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511-6.
8. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998;110:443-9.
9. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998;4:1393-403.
10. Bai XZ, Masters JR, O'Donoghue N, et al. Prognostic markers in clinically localised prostate cancer. Int J Oncol 1999;14:785-91.
11. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenin-dependent prostate cancer. Cancer Res 1992;52:6940-4.
12. Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. Int J Mol Med 1998;1:953-9.
13. Kajiwara T, Takeuchi T, Ueki T, et al. Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol 1999;6:520-5.
14. L in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000;60:6052-60.
15. L underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 2001;61:1699-706.
16. L and bak expression. Clin Cancer Res 1997;3:2039-46.
17. Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997;70:341-8.
18. Tu SM, McConnel K, Marin MC, et al. Combination Adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 1995;93:147-55.
19. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995;11:2477-86.
20. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CSH, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci U S A 1996;93:9160-5.
21. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004;22:929-79.
22. Huang EY, Madireddi MT, Gopalkrishnan RV, et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001;20:7051-63.
23. Fisher PB, Sarkar D, Lebedeva IV, et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol. In press 2007.
24. Fisher PB. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res 2005;65:10128-38.
25. Gupta P, Su Z-z, Lebedeva IV, et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006;111:596-628.
26. Lebedeva IV, Sauane M, Gopalkrishnan RV, et al. mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther 2005;11:4-18.
27. Ramesh R, Mhashilkar AM, Tanaka F, et al. Melanoma differentiation- associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003;63:5105-13.
28. Yacoub A, Mitchell C, Lebedeva IV, et al. mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling. Cancer Biol Ther 2003;2:347-53.
29. Su Z-z, Lebedeva IV, Sarkar D, et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radio-sensitization in malignant gliomas in a p53-independent manner. Oncogene 2003;22:1164-80.
30. Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002;168:6041-6.
31. Poindexter NJ, Walch ET, Chada S, Grimm EA. Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. J Leukoc Biol 2005;78:745-52. Epub 2005 Jul 6.
32. Su Z-z, Emdad L, Sauane M, et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 2005;24:7552-66.
33. Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005;11:149-59.
34. Tong AW, Nemunaitis J, Su D, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005;11:160-72.
35. Lebedeva IV, Su Z-z, Chang Y, Kitada S, Reed JC, Fisher PB. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 2002;21:708-18.
36. L differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 2003;22:8758-73.
37. Sarkar D, Su Z-z, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A 2005;102:14034-9.
38. Sarkar D, Su Z-z, Vozhilla N, et al. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 2005;65:9056-63.
39. Su ZZ, Shi Y, Fisher PB. Subtraction hybridization identifies a progression elevated gene PEG-3 with sequence homology to a growth arrest and DNA damage inducible gene. Proc Natl Acad Sci U S A 1997;94:9125-30.
40. Su ZZ, Shi Y, Fisher PB. Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene 2000;19:3411-21.
41. Su Z-z, Sarkar D, Emdad L, et al. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci U S A 2005;102:1059-64.
42. Gopalkrishnan RV, Kang DC, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 2001;189:245-56.
43. Small EJ, Schellhammer PF, Higano CS, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006;14:107-17.
44. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003;63:7497-506.
45. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464-72.
46. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
47. Thomas MA, Spencer JF, La Regina MC, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006;66:1270-6.
48. Miyahara R, Banerjee S, Kawano K, et al. Melanoma differentiation- associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. Cancer Gene Ther 2006;13:753-61.
49. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61.
50. Tsai V, Johnson DE, Rahmnan A, et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004;10:7199-206.